SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302303839> ?p ?o ?g. }

Showing items 1 to 100 of ±152 with 100 items per page.

W4302303839 abstract "Haemodialysis patients respond poorly to vaccination and continue to be at-risk for severe COVID-19. Therefore, dialysis patients were among the first for which a fourth COVID-19 vaccination was recommended. However, targeted information on how to best maintain immune protection after SARS-CoV-2 vaccinations in at-risk groups for severe COVID-19 remains limited. We provide, to the best of our knowledge, for the first time longitudinal vaccination response data in dialysis patients and controls after a triple BNT162b2 vaccination and in the latter after a subsequent fourth full-dose of mRNA-1273. We analysed systemic and mucosal humoral IgG responses against the receptor-binding domain (RBD) and ACE2-binding inhibition towards variants of concern including Omicron and Delta with multiplex-based immunoassays. In addition, we assessed Spike S1-specific T-cell responses by interferon γ release assay. After triple BNT162b2 vaccination, anti-RBD B.1 IgG and ACE2 binding inhibition reached peak levels in dialysis patients, but remained inferior compared to controls. Whilst we detected B.1-specific ACE2 binding inhibition in 84% of dialysis patients after three BNT162b2 doses, binding inhibition towards the Omicron variant was only detectable in 38% of samples and declining to 16% before the fourth vaccination. By using mRNA-1273 as fourth dose, humoral immunity against all SARS-CoV-2 variants tested was strongly augmented with 80% of dialysis patients having Omicron-specific ACE2 binding inhibition. Modest declines in T-cell responses in dialysis patients and controls after the second vaccination were restored by the third BNT162b2 dose and significantly increased by the fourth vaccination. Our data support current advice for a four-dose COVID-19 immunisation scheme for at-risk individuals such as haemodialysis patients. We conclude that administration of a fourth full-dose of mRNA-1273 as part of a mixed mRNA vaccination scheme to boost immunity and to prevent severe COVID-19 could also be beneficial in other immune impaired individuals. Additionally, strategic application of such mixed vaccine regimens may be an immediate response against SARS-CoV-2 variants with increased immune evasion potential." @default.
W4302303839 created "2022-10-06" @default.
W4302303839 creator A5002780892 @default.
W4302303839 creator A5006282362 @default.
W4302303839 creator A5007893042 @default.
W4302303839 creator A5017998451 @default.
W4302303839 creator A5018433034 @default.
W4302303839 creator A5021793010 @default.
W4302303839 creator A5022087100 @default.
W4302303839 creator A5025026489 @default.
W4302303839 creator A5037735620 @default.
W4302303839 creator A5041076595 @default.
W4302303839 creator A5042082163 @default.
W4302303839 creator A5051705174 @default.
W4302303839 creator A5052579693 @default.
W4302303839 creator A5053999132 @default.
W4302303839 creator A5061440455 @default.
W4302303839 creator A5070896162 @default.
W4302303839 creator A5078154052 @default.
W4302303839 creator A5079441890 @default.
W4302303839 creator A5087799821 @default.
W4302303839 creator A5089021067 @default.
W4302303839 date "2022-10-06" @default.
W4302303839 modified "2023-10-16" @default.
W4302303839 title "Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients" @default.
W4302303839 cites W1976852108 @default.
W4302303839 cites W2072446828 @default.
W4302303839 cites W3082521432 @default.
W4302303839 cites W3124144456 @default.
W4302303839 cites W3126498743 @default.
W4302303839 cites W3131755888 @default.
W4302303839 cites W3164711393 @default.
W4302303839 cites W3167306842 @default.
W4302303839 cites W3177181935 @default.
W4302303839 cites W3177819637 @default.
W4302303839 cites W3183904285 @default.
W4302303839 cites W3189028477 @default.
W4302303839 cites W3196397911 @default.
W4302303839 cites W3196706653 @default.
W4302303839 cites W3199923482 @default.
W4302303839 cites W3204661328 @default.
W4302303839 cites W3210401977 @default.
W4302303839 cites W3212101057 @default.
W4302303839 cites W3214392375 @default.
W4302303839 cites W3216033847 @default.
W4302303839 cites W4207047906 @default.
W4302303839 cites W4210414557 @default.
W4302303839 cites W4210493562 @default.
W4302303839 cites W4210536286 @default.
W4302303839 cites W4210664421 @default.
W4302303839 cites W4210708247 @default.
W4302303839 cites W4212931977 @default.
W4302303839 cites W4213143712 @default.
W4302303839 cites W4214581146 @default.
W4302303839 cites W4214828625 @default.
W4302303839 cites W4220689791 @default.
W4302303839 cites W4220770600 @default.
W4302303839 cites W4220988150 @default.
W4302303839 cites W4221071417 @default.
W4302303839 cites W4223417855 @default.
W4302303839 cites W4223436440 @default.
W4302303839 cites W4224064109 @default.
W4302303839 cites W4224268482 @default.
W4302303839 cites W4225310481 @default.
W4302303839 cites W4225937314 @default.
W4302303839 cites W4226343533 @default.
W4302303839 cites W4229367228 @default.
W4302303839 cites W4280524065 @default.
W4302303839 cites W4280587892 @default.
W4302303839 cites W4280607167 @default.
W4302303839 cites W4280610129 @default.
W4302303839 cites W4280652613 @default.
W4302303839 cites W4281291961 @default.
W4302303839 cites W4281389349 @default.
W4302303839 cites W4281687206 @default.
W4302303839 cites W4281965332 @default.
W4302303839 cites W4283019020 @default.
W4302303839 cites W4283122765 @default.
W4302303839 cites W4283331044 @default.
W4302303839 cites W4284689791 @default.
W4302303839 cites W4285499891 @default.
W4302303839 cites W4289887015 @default.
W4302303839 cites W4292227878 @default.
W4302303839 cites W4292317872 @default.
W4302303839 cites W4293150197 @default.
W4302303839 doi "https://doi.org/10.3389/fimmu.2022.1004045" @default.
W4302303839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36275672" @default.
W4302303839 hasPublicationYear "2022" @default.
W4302303839 type Work @default.
W4302303839 citedByCount "10" @default.
W4302303839 countsByYear W43023038392022 @default.
W4302303839 countsByYear W43023038392023 @default.
W4302303839 crossrefType "journal-article" @default.
W4302303839 hasAuthorship W4302303839A5002780892 @default.
W4302303839 hasAuthorship W4302303839A5006282362 @default.
W4302303839 hasAuthorship W4302303839A5007893042 @default.
W4302303839 hasAuthorship W4302303839A5017998451 @default.
W4302303839 hasAuthorship W4302303839A5018433034 @default.
W4302303839 hasAuthorship W4302303839A5021793010 @default.
W4302303839 hasAuthorship W4302303839A5022087100 @default.